Active Anchoring Stimuli‐Responsive Nano‐Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Mingxing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Myocytes, Smooth Muscle, Pulmonary Artery. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Recently, nanotechnology‐based drug delivery platforms in treating pulmonary arterial hypertension (PAH) have gradually emerged. However, large mechanical stress and shear stress in blood vessels greatly affect the retention of nanopreparative materials at lesion sites, severely limiting nanotechnology‐based drug delivery. Herein, a stimuli‐responsive nanocraft is rationally designed by actively anchoring E‐selectin overexpressed on pulmonary arterial endothelial cells (PAECs), under hypoxic conditions, allowing effective accumulation and retention of the drug at the lesion site. Briefly, a nitrobenzene group is incorporated into the framework of a nanocarrier, and then it is simultaneously linked with chitosan. Additionally, the surface of the nanocarrier with sialic acid (SA) and encapsulated the clinically used drug ambrisentan (Am), which enables the anchoring of E‐selectin and subsequent drug delivery is modifed. This system facilitates intercellular transport to pulmonary artery smooth muscle cells (PASMCs) when targeting PAECs and specifically responds to a reductive hypoxic microenvironment with elevated nitroreductase in PASMCs. Moreover, compared with free Am, nanoencapsulation and SA‐PEG 2000 ‐NH 2 prolong the blood circulation time, achieving better therapeutic outcomes in preventing vascular remodeling and reversing systolic dysfunction. The originality and contribution of this work reveal the promising value of this pulmonary arterial anchoring stimuli‐responsive nanocraft as a novel therapeutic strategy for satisfactory PAH treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
- College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, P. R. China.
- Department of Diagnostic Ultrasound and Echocardiography, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
- National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, 310058, China.
ORCID-Profile: Hong Yuan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Shang, X., Lou, H., Wang, Z., Xiang, S., Qiu, Y., Hu, F., Yu, F., & Yuan, H. (2024). Active Anchoring Stimuli‐Responsive Nano‐Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400113
Vancouver
Li M, Shang X, Lou H, Wang Z, Xiang S, Qiu Y, et al. Active Anchoring Stimuli‐Responsive Nano‐Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400113
BibTeX
@article{Li2024,
author = {Li, Mingxing and Shang, Xuwei and Lou, Haiya and Wang, Zixu and Xiang, Shanshan and Qiu, Yihe and Hu, Fuqiang and Yu, Fangying and Yuan, Hong},
title = {Active Anchoring Stimuli‐Responsive Nano‐Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400113}
}
EUVIMED